
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Biotech Catalyst Calendar 2026: PDUFA & FDA Dates
FDA decisions, PDUFA dates, advisory committees and clinical-trial readouts for publicly traded biotech stocks.
Tables updated: November 17, 2026; glossary reviewed: September 19, 2026This is Merlintrader’s dedicated biotech catalyst calendar. It tracks upcoming FDA decisions, PDUFA target dates, advisory committee meetings, NDA and BLA milestones, regulatory submissions and major clinical-trial readouts for publicly traded biotech and healthcare companies, including selected non-U.S. listings with FDA milestones.
This page lists the confirmed FDA regulatory deadlines (PDUFA target dates and other FDA decisions), each with its date, company context and source trail, followed by the embedded event calendar, the AI catalyst lookup and a glossary. The complete calendar, with clinical readouts, conference presentations, estimated company windows and recent history, is in the Catalyst Total Tracker.
Catalyst dates can change, FDA decisions can arrive early or late and clinical readouts can be postponed. Always confirm each event against company filings, official press releases and regulatory sources before making any trading or investment decision.
Upcoming PDUFA and FDA decision dates
This table is an editorial selection of confirmed FDA regulatory deadlines supported by primary sources. A PDUFA date is a review goal, not a promise of approval, and the FDA can act early or late.
Confirmed regulatory deadlines: 60 events
| Date / window | Ticker | Company | Event | Status | Sources |
|---|---|---|---|---|---|
| 2026-11-22 | $CAPR | CAPRICOR THERAPEUTICS, INC. | Deramiocel (CAP-1002), cell therapy — Duchenne muscular dystrophy; refined proposed indication focused on upper limb function. FDA review of the BLA major amendment includes 24-month HOPE-3 open-label extension data and robustness analyses. On 24 August 2026 Capricor announced a three-month extension from 22 August to 22 November 2026. The target date is not an approval. | Confirmed date | SEC filing |
| 2026-11-22 | $SVRA | Savara Inc. | Molbreevi (molgramostim), inhalation solution — autoimmune pulmonary alveolar proteinosis date extended by three months for a major amendment. | Confirmed date | Primary source |
| 2026-11-25 | $SNY | Sanofi | Venglustat, oral glucosylceramide synthase inhibitor — Gaucher disease type 3, neurological manifestations. | Confirmed date | SEC filing |
| 2026-11-27 | $BBIO | BridgeBio Pharma, Inc. | BBP-418 — limb-girdle muscular dystrophy LGMD2I/R9. | Confirmed date | Primary source |
| 2026-11-27 | $GSK | GSK | Neladalkib (NVL-655) — advanced ALK-positive NSCLC, previously treated with TKI formerly a Nuvalent asset, acquired by GSK on 15 July 2026. | Confirmed date | Primary source Supporting source |
| 2026-11-27 | $RPRX | Royalty Pharma plc | Neladalkib — ALK-positive non-small cell lung cancer; royalty interest. FDA target action date: 2026-11-27. | Confirmed date | SEC filing |
| 2026-11-28 | $PYPD | PolyPid Ltd. | D-PLEX100, local prolonged-release doxycycline depot — prevention of surgical site infections in colorectal surgery. | Confirmed date | Primary source |
| 2026-11-30 | $COGT | Cogent Biosciences, Inc. | Bezuclastinib, with sunitinib — gastrointestinal stromal tumours previously treated with imatinib. | Confirmed date | Primary source |
| 2026-11-30 | $VRTX | VERTEX PHARMACEUTICALS INCORPORATED | Povetacicept, dual BAFF and APRIL inhibitor — IgA nephropathy, accelerated approval pathway. | Confirmed date | Primary source |
| 2026-11-30 | $ZLAB | Zai Lab Limited | Povetacicept, a dual APRIL/BAFF inhibitor developed by Vertex with Zai Lab as partner, for IgA nephropathy: the FDA target action date is November 30, 2026. | Confirmed date | SEC filing |
| 2026-12-12 | $ANAB | ANAPTYSBIO, INC | Quimilza (imsidolimab) for generalized pustular psoriasis, with Vanda as AnaptysBio's partner: the FDA target action date is December 12, 2026. | Confirmed date | SEC filing |
| 2026-12-12 | $VNDA | Vanda Pharmaceuticals Inc. | Imsidolimab, IL-36R antagonist — generalized pustular psoriasis molecule originated by AnaptysBio, BLA held by Vanda. | Confirmed date | Primary source |
| 2026-12-17 | $CORT | Corcept Therapeutics Incorporated | Relacorilant, selective glucocorticoid receptor antagonist — Cushing's syndrome NDA resubmitted on 17 June 2026 after a CRL on this indication. | Confirmed date | SEC filing |
| 2026-12-22 | $MLYS | Mineralys Therapeutics, Inc. | Lorundrostat NDA for the treatment of hypertension in adults, in combination with other antihypertensive drugs: the FDA target action date (PDUFA) is December 22, 2026. | Confirmed date | Primary source |
| 2026-12-23 | $GILD | GILEAD SCIENCES, INC. | Anito-cel (anitocabtagene autoleucel), anti-BCMA CAR-T — relapsed or refractory multiple myeloma, fourth line BLA filed by Arcellx, acquired by Gilead on 28 April 2026. | Confirmed date | SEC filing |
| 2026-12-27 | $PRAX | Praxis Precision Medicines, Inc. | Relutrigine NDA for SCN2A and SCN8A developmental and epileptic encephalopathies: the FDA target action date was extended from September 27, 2026 to December 27, 2026 following a major amendment to the application. | Confirmed date | Primary source |
| 2026-12-27 | $VTRS | Viatris Inc. | PDUFA goal date for Viatris' New Drug Application (505(b)(2) pathway) for MR-107A-02, an investigational fast-acting oral formulation of meloxicam (NSAID) for the treatment of moderate-to-severe acute pain, positioned as a non-opioid option; the FDA accepted the NDA for review, as announced on May 18, 2026. The product has not been approved by any regulatory authority. | Confirmed date | Primary source Supporting source |
| 2026-12-30 | $COGT | Cogent Biosciences, Inc. | Bezuclastinib monotherapy — non-advanced systemic mastocytosis. | Confirmed date | Primary source |
| 2027-01-21 | $DYN | Dyne Therapeutics, Inc. | Zeleciment rostudirsen (z-rostudirsen, DYNE-251) for Duchenne muscular dystrophy in patients amenable to exon 51 skipping: the FDA target action date is January 21, 2027. | Confirmed date | Primary source |
| 2027-01-29 | $PRAX | Praxis Precision Medicines, Inc. | Ulixacaltamide NDA for essential tremor: the FDA target action date is January 29, 2027. | Confirmed date | SEC filing |
| 2027-01-30 | $PHAR | Pharming Group N.V. | Pharming Group: FDA accepted with Priority Review (September 28, 2026) a supplemental NDA for Joenja (leniolisib) covering twice-daily dosing for APDS patients weighing 13 to 27 kg (extending the existing approval for patients 4-11 years old weighing at least 27 kg). PDUFA target action date January 30, 2027. Disclosed in the company's third-quarter 2026 financial results. | Confirmed date | SEC filing |
| 2027-02-01 | $AGIO | Agios Pharmaceuticals, Inc. | FDA extended the mitapivat sickle cell disease sNDA review from November 1, 2026 to February 1, 2027 after classifying Agios’ response on potential REMS requirements as a major amendment. Labeling discussions continue. The goal date is an agency action target, not an approval decision. | Confirmed date | Primary source |
| 2027-02-04 | $BBIO | BridgeBio Pharma, Inc. | FDA accepted the NDA with Priority Review and assigned a February 4, 2027 PDUFA target, per the October 6 company announcement. Review acceptance is not approval. | Confirmed date | Primary source |
| 2027-02-07 | $VSTM | Verastem, Inc. | The FDA has accepted Verastem Oncology's New Drug Application for the AVMAPKI FAKZYNJA CO-PACK (avutometinib capsules; defactinib tablets) blister pack under Priority Review, with an FDA decision expected by February 7, 2027. Acceptance was communicated on October 14, 2026 and reiterated on November 5, 2026. | Confirmed date | SEC filing |
| 2027-02-12 | $BLTE | BELITE BIO, INC | Tinlarebant NDA for Stargardt disease type 1: the FDA target action date is February 12, 2027. | Confirmed date | Primary source |
| 2027-02-23 | $ARQT | Arcutis Biotherapeutics, Inc. | ZORYVE (roflumilast) cream 0.05% for atopic dermatitis in infants aged 3 to 24 months: the FDA target action date is February 23, 2027. | Confirmed date | Primary source |
| 2027-02-27 | $CGEM | Cullinan Therapeutics, Inc. | Zipalertinib — EGFR exon 20 insertion non-small cell lung cancer. FDA target action date: 2027-02-27. | Confirmed date | SEC filing |
| 2027-02-28 | $APMD | Apnimed, Inc. | AD109 — obstructive sleep apnea. FDA target action date: 2027-02-28. | Confirmed date | SEC filing |
| 2027-02-28 | $BMRN | BioMarin Pharmaceutical Inc. | Voxzogo (vosoritide) — full approval in children with achondroplasia. FDA target action date: 2027-02-28. | Confirmed date | Primary source |
| 2027-02-28 | $LGND | LIGAND PHARMACEUTICALS INC | PDUFA: QTORIN 3.9% rapamycin anhydrous gel (Palvella Therapeutics, a Ligand portfolio program) in microcystic lymphatic malformations. FDA target action date February 28, 2027 under Priority Review; approval is not assured. | Confirmed date | SEC filing SEC filing |
| 2027-02-28 | $PVLA | PALVELLA THERAPEUTICS INC | Regulatory decision: sirolimus (QTORIN rapamycin) – Microcystic lymphatic malformations. FDA accepted the NDA for filing and granted Priority Review on October 28, 2026; confirmed PDUFA target action date February 28, 2027. QTORIN rapamycin also holds Breakthrough Therapy, Fast Track and Orphan Drug designations for this indication. A standalone U.S. launch is planned for H1 2027, subject to approval. | Confirmed date | SEC filing |
| 2027-02-28 | $SRPT | Sarepta Therapeutics, Inc. | AMONDYS 45 and VYONDYS 53 — Duchenne muscular dystrophy; traditional approval conversion. FDA target action date: 2027-02-28. | Confirmed date | Primary source |
| 2027-03-03 | $EXEL | EXELIXIS, INC. | Zanzalintinib + atezolizumab — previously treated metastatic colorectal cancer, STELLAR-303 New target March 3, 2027; December 3, 2026 is no longer an active deadline. FDA notified the company on September 10 that new safety and efficacy data constituted a major amendment; filing dated September 11. | Confirmed date | Primary source |
| 2027-03-10 | $NTLA | Intellia Therapeutics, Inc. | Lonvoguran ziclumeran (lonvo-z/NTLA-2002) for hereditary angioedema: BLA accepted with Priority Review, FDA PDUFA target March 10, 2027. Approval is not assured. One application, one event. | Confirmed date | Primary source SEC filing |
| 2027-03-11 | $BMY | BRISTOL MYERS SQUIBB | Reblozyl (luspatercept) — myelofibrosis-associated anemia. FDA target action date: 2027-03-11. | Confirmed date | SEC filing |
| 2027-03-16 | $AQST | Aquestive Therapeutics, Inc. | FDA goal date (PDUFA) for the resubmitted NDA of Anaphylm (dibutepinephrine) sublingual film for the treatment of Type I allergic reactions, including anaphylaxis. The FDA accepted the resubmission, filed on September 16, 2026, as complete and classified it as a Class 2 response (announced October 15, 2026). | Confirmed date | SEC filing |
| 2027-03-22 | $MRK | Merck & Co., Inc. | Enflonsia (clesrovimab-cfor) — children entering a second RSV season at increased risk. FDA target action date: 2027-03-22. | Confirmed date | Primary source |
| 2027-03-23 | $AQST | Aquestive Therapeutics, Inc. | FDA goal date (PDUFA) of March 23, 2027 for final approval of LIBERVANT (diazepam) buccal film for patients twelve years of age and older, which is also subject to the expiration of orphan drug exclusivity for Valtoco on January 10, 2027. LIBERVANT has tentative FDA approval for patients two to five and twelve years of age and older; a separate application for ages six to eleven has a PDUFA date of March 29, 2027. Eton Pharmaceuticals holds the exclusive U.S. commercialization rights. | Confirmed date | SEC filing |
| 2027-03-25 | $UNCY | Unicycive Therapeutics, Inc. | PDUFA target action date for the resubmitted NDA of oxylanthanum carbonate (OLC), oral phosphate binder for hyperphosphatemia in patients with chronic kidney disease on dialysis. The FDA accepted the resubmission, filed after a Complete Response Letter in June 2026, as a Class II resubmission with a six-month review period from the resubmission date. The resubmission includes CMC data from a new third-party drug product manufacturing vendor; the company does not know whether the FDA will conduct a pre-approval inspection of that vendor. | Confirmed date | Finviz (news) |
| 2027-03-29 | $AQST | Aquestive Therapeutics, Inc. | FDA goal date (PDUFA) for the LIBERVANT (diazepam) buccal film application for patients aged 6 to 11 with seizure clusters, as cited in the October 14, 2026 Eton/Aquestive license announcement. Eton holds the exclusive U.S. commercial rights; Aquestive is the exclusive manufacturer and receives milestones and royalties. | Confirmed date | Primary source |
| 2027-03-29 | $ETON | ETON PHARMACEUTICALS INC | FDA goal date (PDUFA) for the LIBERVANT (diazepam) buccal film application for patients aged 6 to 11 with seizure clusters. Eton licensed exclusive U.S. rights from Aquestive on October 13, 2026 ($10.0 million upfront, up to $47.5 million in milestones, mid-teens royalties). | Confirmed date | Primary source SEC filing |
| 2027-03-31 | $ATRA | Atara Biotherapeutics, Inc. | FDA accepted the Class 2 resubmission of the tabelecleucel (tab-cel) Biologics License Application for Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD), announced October 14, 2026 by partner Pierre Fabre Pharmaceuticals. New PDUFA goal date: March 31, 2027. | Confirmed date | Primary source |
| 2027-04-01 | $HRMY | Harmony Biosciences Holdings, Inc. | Pitolisant GR for narcolepsy: the FDA target action date for the New Drug Application is April 1, 2027. | Confirmed date | SEC filing |
| 2027-04-14 | $INBX | INHIBRX BIOSCIENCES INC | PDUFA: ozekibart (INBRX-109) · Conventional chondrosarcoma. Company timing: 14 April 2027. FDA target action date; approval is not assured. | Confirmed date | SEC filing |
| 2027-04-22 | $MRK | Merck & Co., Inc. | FDA PDUFA target action date of April 22, 2027 for two supplemental New Drug Applications for IDVYNSO (doravirine/islatravir) accepted by the FDA: one based on the Phase 3 Trial 053 in adults who had not previously received antiretroviral treatment, and one based on the Phase 3 Trials 051 and 052 to include 96-week data in virologically suppressed adults. | Confirmed date | Primary source |
| 2027-04-23 | $PHVS | Pharvaris N.V. | Deucrictibant immediate-release capsules (deucrictibant IR) for the on-demand treatment of hereditary angioedema attacks: the FDA target action date is April 23, 2027. | Confirmed date | Primary source |
| 2027-04-23 | $RPRX | Royalty Pharma plc | Deucrictibant IR — hereditary angioedema; royalty interest. FDA target action date: 2027-04-23. | Confirmed date | SEC filing |
| 2027-04-24 | $ORGO | Organogenesis Holdings Inc. | ReNu — symptomatic knee osteoarthritis. FDA target action date: 2027-04-24. | Confirmed date | Primary source |
| 2027-04-28 | $IMNM | IMMUNOME, INC. | Varegacestat (formerly AL102) NDA for desmoid tumors in adults: the FDA target action date is April 28, 2027. | Confirmed date | Primary source |
| 2027-05-01 | $AXSM | Axsome Therapeutics, Inc. | AXS-12 (reboxetine) NDA for narcolepsy: the FDA target action date is May 1, 2027. | Confirmed date | SEC filing |
| 2027-05-01 | $QURE | uniQure N.V. | FDA PDUFA target action date of May 1, 2027 for the Biologics License Application for ifezuntirgene inilparvovec (AMT-130), an investigational gene therapy for Huntington's disease, submitted under the Accelerated Approval pathway and granted Priority Review. In its acceptance letter the FDA stated that it is tentatively planning to discuss the application at an Advisory Committee meeting; the date has not been set and uniQure will be notified once the date and timelines are finalized. | Confirmed date | SEC filing |
| 2027-05-08 | $BBIO | BridgeBio Pharma, Inc. | Encaleret — autosomal dominant hypocalcemia type 1. FDA target action date: 2027-05-08. | Confirmed date | SEC filing |
| 2027-05-13 | $BMY | BRISTOL MYERS SQUIBB | Mezigdomide with carfilzomib and dexamethasone — relapsed/refractory multiple myeloma. FDA target action date: 2027-05-13. | Confirmed date | SEC filing |
| 2027-05-27 | $XNCR | XENCOR INC | PDUFA: obexelimab (Zenas BioPharma; licensed by Xencor in November 2021, XmAb Immune Inhibitor Fc Domain) in IgG4-related disease. The BLA was submitted in May 2026 and accepted by the FDA in August 2026 with a PDUFA target action date of May 27, 2027. Approval is not assured. | Confirmed date | SEC filing SEC filing |
| 2027-05-27 | $ZBIO | Zenas BioPharma, Inc. | Obexelimab — IgG4-related disease. FDA target action date: 2027-05-27. | Confirmed date | Primary source |
| 2027-05-28 | $ETON | ETON PHARMACEUTICALS INC | The FDA has accepted for review Eton Pharmaceuticals' Prior Approval Supplement (PAS) for KHINDIVI (hydrocortisone), which seeks to expand the indicated age range to include children under five, and assigned a PDUFA date of May 28, 2027; if approved, Eton anticipates commercial launch shortly after approval. Reported November 5, 2026. | Confirmed date | SEC filing |
| 2027-06-14 | $URGN | UROGEN PHARMA LTD | PDUFA: UGN-103 (mitomycin) for intravesical solution · recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen announced on October 19, 2026 that the FDA accepted the NDA, with a PDUFA target action date of June 14, 2027. Supported by the Phase 3 UTOPIA trial. | Confirmed date | Primary source |
| 2027-06-24 | $UTHR | UNITED THERAPEUTICS CORPORATION | Ralinepag — pulmonary arterial hypertension. FDA target action date: 2027-06-24. | Confirmed date | Primary source |
| 2027-06-28 | $KPTI | Karyopharm Therapeutics Inc. | PDUFA target action date of June 28, 2027 for Karyopharm's supplemental New Drug Application for XPOVIO (selinexor) in combination with ruxolitinib for patients with myelofibrosis, accepted by the FDA as announced on November 17, 2026. The sNDA is primarily based on the Phase 3 SENTRY trial (NCT04562389). The announcement does not mention Priority Review or an advisory committee meeting. Karyopharm is in Chapter 11 and its stock trades over the counter as KPTIQ. | Confirmed date | Primary source |
| 2027-06-29 | $COGT | Cogent Biosciences | Bezuclastinib NDA in advanced systemic mastocytosis (AdvSM): FDA target action date June 29, 2027, announced September 15. Separate from GIST November 30 and nonadvanced SM December 30, 2026. Approval is not assured. | Confirmed date | Primary source |
You can find the complete calendar in the Catalyst Total Tracker.
Catalysts by month: December 2026
Biotech Catalyst Lookup
Type a ticker to get an AI-generated snapshot of the next catalyst (PDUFA, clinical data, regulatory events) with a link to the primary source.
Automatically generated AI snapshot
Enter a ticker to receive a snapshot generated by artificial intelligence using web sources. Responses are not individually checked by a person before they are displayed.
Dates, events and sources may be incomplete, incorrect or out of date. Check the information against official company releases, SEC filings, FDA documents or ClinicalTrials.gov. Estimated dates are not firm deadlines.
For information and education only. Not investment advice or a recommendation to buy or sell securities.
Read the full disclaimerRecently viewed catalysts
CGONClinical
CG Oncology, Inc. (NASDAQ: CGON)
Late-breaking podium presentation of PIVOT-006 Phase 3 topline results at the Society of Urologic Oncology (SUO) Annual Meeting
2026-12-02
AKBACatalyst
Akebia Therapeutics, Inc. (Nasdaq: AKBA)
End of Vafseo TDAPA reimbursement period and start of the 2027 post-TDAPA add-on payment adjustment
2027-01-01
UNCYPDUFA
Unicycive Therapeutics, Inc. (Nasdaq: UNCY)
FDA decision (PDUFA target action date) on the resubmitted NDA for oxylanthanum carbonate (OLC)
2027-03-25
KPTIPDUFA
Karyopharm Therapeutics Inc. (KPTI; OTC: KPTIQ since November 11, 2026)
FDA decision on supplemental New Drug Application for XPOVIO (selinexor) in combination with ruxolitinib for myelofibrosis (accelerated approval pathway)
2027-06-28
PRLDClinical
Prelude Therapeutics Incorporated (Nasdaq: PRLD)
Initial proof-of-concept clinical data from the Phase 1 study of PRT13722, a KAT6A oral degrader, in HR+/HER2- breast cancer
2nd half of 2027
SLSRegulatory
SELLAS Life Sciences Group, Inc. (NASDAQ: SLS)
Biologics License Application (BLA) submission for galinpepimut-S (GPS) in AML, following a planned FDA meeting on an accelerated filing strategy
First half 2027
SRRKRegulatory
Scholar Rock Holding Corporation (NASDAQ: SRRK)
CHMP opinion on the resubmitted apitegromab Marketing Authorisation Application (MAA) for spinal muscular atrophy (SMA) in the EU
H1 2027
LXEOCatalyst
Lexeo Therapeutics, Inc.
Finalization of the pivotal study design, statistical analysis plan and confirmatory strategy for LX2020 in PKP2 arrhythmogenic cardiomyopathy, subject to FDA discussions
H1 2027
HCMRegulatory
HUTCHMED (CHINA) LIMITED (ticker HCM)
FDA review of the US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer; FDA action date not disclosed
Not available
OLMAClinical
Olema Oncology, Inc. (formerly Olema Pharmaceuticals, Inc.; Nasdaq: OLMA)
Top-line data from the pivotal Phase 3 OPERA-01 trial of palazestrant
Q1 2027
IBIOClinical
iBio, Inc.
Interim Phase 1 single-ascending-dose (SAD) data for IBIO-600 in overweight or obese adults
Q1 2027
OCSClinical
Oculis Holding AG (Nasdaq: OCS)
PREDICT-1 registrational topline data for licaminlimab in genotype-selected dry eye disease (company guidance per Merlintrader tracker, not confirmed in an official release)
Year-end 2026
Catalyst Calendar Glossary
Quick definitions for FDA, clinical-trial, and “catalyst” terms used in the calendar & trackers.
1) FDA / Regulatory
| Term | Meaning |
|---|---|
| PDUFA date | FDA target action date for an NDA/BLA decision (often disclosed via filings/press releases). |
| Priority Review | FDA review goal generally 6 months; the clock depends on the application type. It does not guarantee approval or a decision on a fixed date. |
| Standard Review | FDA review goal generally 10 months; clock start and pathway depend on the application. |
| AdCom | Advisory committee: reviews evidence and may vote; a meeting does not imply approval and its advice is not binding on FDA. |
| NDA / BLA | Applications to approve a drug (NDA) or a biologic (BLA). |
| sNDA / sBLA | Supplemental application (label expansion, new population, new formulation, etc.). |
| Filing acceptance | FDA accepts the application as sufficiently complete to start review (often when PDUFA is set). |
| RTF (Refuse-to-File) | FDA declines to accept an application for review (formal/technical deficiencies). |
| CRL (Complete Response Letter) | FDA does not approve at that time and requests additional info/changes before resubmission. |
| Resubmission (Class 1 / Class 2) | Re-file after CRL; Class 1 = minor changes (often shorter), Class 2 = major (often longer). |
| PDUFA delay/extension | FDA pushes the action date (more time needed for review, inspections, analyses, etc.). |
2) FDA Meetings
| Term | Meaning |
|---|---|
| Type A | Urgent/critical meeting (clinical hold, disputes, time-sensitive issues). |
| Type B | Standard “milestone” meeting (End-of-Phase, pre-NDA/BLA, etc.). |
| Type C | Other focused meeting on specific topics; can still be strategically important. |
| EOP (End-of-Phase) | Aligns requirements to move forward (next phase / registrational plan / filing path). |
| SPA | Special Protocol Assessment: FDA agrees in advance on design/endpoint of a key trial (not a guarantee). |
3) Trial Progress vs Data Release
| Term | Meaning | Data released? |
|---|---|---|
| Enrollment Initiation | First sites/patients start enrolling. | NO |
| Enrollment Complete | Enrollment finished (no more new patients). | NO |
| Trial Completed | Final protocol-defined data collection completed. Primary completion concerns primary outcomes; study completion includes secondary outcomes and adverse events. Neither means results have been published. | NO |
| Database Lock | Dataset is finalized for analysis (internal milestone). | NO |
| Interim Data | Results from an interim analysis, which may remain internal. They count as released data only when publicly disclosed. | IF DISCLOSED |
| Topline Data | High-level results release (often via PR/filing). | YES |
| Data Released / Readout | Results publicly disclosed; internal analysis alone does not constitute a public readout. | YES |
| Full Results / Full Dataset | Detailed results published or presented; does not necessarily mean access to the full raw dataset. | YES |
| Conference Presentation | Abstract, poster or oral presentation. A scheduled slot alone does not establish that new results have been released. | IF DISCLOSED |
| Publication | Peer-reviewed paper / full write-up. | YES |
Key rule: “Trial Completed” ≠ “Data Released”. Completion is an operational milestone; data can come weeks/months later.
4) Common Clinical Metrics
| Term | Meaning |
|---|---|
| OS | Overall Survival. |
| PFS | Progression-Free Survival. |
| ORR | Objective Response Rate (CR + PR). |
| CR / PR | Complete / Partial Response. |
| SD / PD | Stable Disease / Progressive Disease. |
| DOR | Duration of Response. |
| AE / SAE | Adverse event / serious adverse event under regulatory criteria, such as death, life-threatening events or hospitalization. Seriousness differs from severity of intensity; causation is not automatic. |
| PK / PD | Pharmacokinetics / Pharmacodynamics. |
| Biomarker | Biological marker used for selection/response/target engagement. |
5) “Accelerators” / Designations
| Term | Meaning |
|---|---|
| ODD | Orphan Drug Designation (rare-disease incentives). |
| FTD | Fast Track Designation (more frequent interactions; potential rolling submission). |
| BTD | Breakthrough Therapy Designation: preliminary clinical evidence of potential substantial improvement on clinically significant endpoints over available therapies for a serious condition. It is not approval. |
| RMAT | Designation for eligible regenerative therapies, including certain cell, tissue and gene therapies, with preliminary clinical evidence of potential to address unmet needs in serious conditions. It is not approval. |
| RPDD / PRV | RPDD is a rare pediatric disease designation. A PRV is a separate voucher that may be awarded with a qualifying approval and transferred or used to request priority review of another application. Designation guarantees neither a voucher nor approval. |
6) Calendar Fields (how to read them)
| Field | Meaning |
|---|---|
| Stage | Program phase (Preclinical, Phase 1/2/3, NDA/BLA Filing, PDUFA, etc.). |
| Status | Operational status (Ongoing, Trial Completed, Data Released, Clinical Hold, etc.). |
| Next catalyst | Next expected milestone (Topline, Interim, Conference, Submission, Regulatory Decision). |
| Catalyst date | Date or time window (exact / month / quarter / half / year / range). |
Glossary sources: FDA BTD · FDA RMAT · FDA RPDD/PRV · FDA SAE · ClinicalTrials.gov
Important Disclaimer
The dates and events shown in this calendar are collected from publicly available sources and company communications, but may change at any time and may contain errors, inaccuracies, delays or omissions. Some dates are estimated, some timelines may be revised, and certain catalysts may be postponed, cancelled or updated without notice. Always verify with official press releases, SEC filings and primary company sources before making any trading or investment decision.
This content is for educational and informational purposes only. It is not investment advice and not a recommendation to buy or sell any security. Do your own research and consult a licensed advisor. Full disclaimer: merlintrader.com/disclaimer.



